Jane Street’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.86M | Buy |
+90,321
| New | +$2.46M | ﹤0.01% | 4431 |
|
|
2025
Q3 | – | Sell |
-28,860
| Closed | -$669K | – | 10861 |
|
|
2025
Q2 | $587K | Sell |
28,860
-185,566
| -87% | -$3.61M | ﹤0.01% | 6618 |
|
|
2025
Q1 | $3.89M | Buy |
214,426
+128,844
| +151% | +$2.88M | ﹤0.01% | 3302 |
|
|
2024
Q4 | $2.16M | Sell |
85,582
-88,088
| -51% | -$2.39M | ﹤0.01% | 3969 |
|
|
2024
Q3 | $5.9M | Sell |
173,670
-16,659
| -9% | -$635K | ﹤0.01% | 2601 |
|
|
2024
Q2 | $7.04M | Buy |
190,329
+13,448
| +8% | +$507K | ﹤0.01% | 2479 |
|
|
2024
Q1 | $7.42M | Buy |
176,881
+48,720
| +38% | +$2M | ﹤0.01% | 2122 |
|
|
2023
Q4 | $5.08M | Buy |
128,161
+68,747
| +116% | +$2.02M | ﹤0.01% | 2827 |
|
|
2023
Q3 | $1.64M | Buy |
59,414
+34,457
| +138% | +$1.08M | ﹤0.01% | 4371 |
|
|
2023
Q2 | $847K | Sell |
24,957
-42,902
| -63% | -$1.45M | ﹤0.01% | 5491 |
|
|
2023
Q1 | $2.44M | Buy |
67,859
+24,650
| +57% | +$1.06M | ﹤0.01% | 3479 |
|
|
2022
Q4 | $1.93M | Buy |
43,209
+9,899
| +30% | +$353K | ﹤0.01% | 3931 |
|
|
2022
Q3 | $937K | Sell |
33,310
-142,196
| -81% | -$4.36M | ﹤0.01% | 5515 |
|
|
2022
Q2 | $4.73M | Buy |
175,506
+97,097
| +124% | +$2.82M | ﹤0.01% | 2741 |
|
|
2022
Q1 | $2.67M | Buy |
78,409
+56,209
| +253% | +$1.8M | ﹤0.01% | 4197 |
|
|
2021
Q4 | $858K | Buy |
22,200
+9,952
| +81% | +$434K | ﹤0.01% | 6214 |
|
|
2021
Q3 | $661K | Sell |
12,248
-43,688
| -78% | -$2.05M | ﹤0.01% | 6752 |
|
|
2021
Q2 | $1.87M | Buy |
55,936
+36,572
| +189% | +$1M | ﹤0.01% | 4452 |
|
|
2021
Q1 | $399K | Sell |
19,364
-14,768
| -43% | -$339K | ﹤0.01% | 7210 |
|
|
2020
Q4 | $598K | Buy |
+34,132
| New | +$614K | ﹤0.01% | 5465 |
|
|
2020
Q3 | – | Sell |
-13,876
| Closed | -$163K | – | 7195 |
|
|
2020
Q2 | $180K | Buy |
+13,876
| New | +$61.5K | ﹤0.01% | 6433 |
|
|
2018
Q3 | – | Sell |
-11,808
| Closed | -$89K | – | 5130 |
|
|
2018
Q2 | $89K | Buy |
+11,808
| New | +$158K | ﹤0.01% | 4754 |
|
|
2018
Q1 | – | Sell |
-1,257
| Closed | -$54K | – | 4848 |
|
|
2017
Q4 | $54K | Buy |
1,257
+501
| +66% | +$21.5K | ﹤0.01% | 4420 |
|
|
2017
Q3 | $32K | Buy |
+756
| New | +$28.3K | ﹤0.01% | 4344 |
|
|
2016
Q4 | – | Sell |
-715
| Closed | -$43K | – | 4057 |
|
|
2016
Q3 | $43K | Buy |
+715
| New | +$44.5K | ﹤0.01% | 3899 |
|
|
2016
Q2 | – | Sell |
-2,677
| Closed | -$152K | – | 4102 |
|
|
2016
Q1 | $152K | Sell |
2,677
-2,384
| -47% | -$268K | ﹤0.01% | 3790 |
|
|
2015
Q4 | $1.19M | Buy |
+5,061
| New | +$1.1M | 0.01% | 1566 |
|
|
2015
Q3 | – | Sell |
-646
| Closed | -$244K | – | 3613 |
|
|
2015
Q2 | $244K | Sell |
646
-1,337
| -67% | -$531K | ﹤0.01% | 3053 |
|
|
2015
Q1 | $829K | Buy |
1,983
+1,285
| +184% | +$460K | 0.01% | 1539 |
|
|
2014
Q4 | $191K | Buy |
+698
| New | +$174K | ﹤0.01% | 2242 |
|
|
2013
Q4 | – | Sell |
-4,693
| Closed | -$2.49M | – | 2391 |
|
|
2013
Q3 | $2.49M | Buy |
4,693
+87
| +2% | +$29.8K | 0.03% | 470 |
|
|
2013
Q2 | $1.08M | Buy |
+4,606
| New | +$907K | 0.02% | 840 |
|
Other funds holding CLDX
KCM
VCM
CC
EP
Jane Street's CLDX Position: Q1 2026 in Review
Jane Street opened a new position in Celldex Therapeutics (CLDX) in Q1 2026: 90,321 shares worth $2.86M. The stake represents ﹤0.01% of the portfolio and ranks #4431 among its holdings. This is a return to the name: Jane Street previously reported a position in CLDX as recently as Q2 2025.
Jane Street first reported a position in CLDX in Q2 2013 and has held it in 32 quarters since. The position peaked at $7.42M in Q1 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.
- Jane Street held 90,321 shares of Celldex Therapeutics worth $2.86M as of Q1 2026.
- Celldex Therapeutics was a new Jane Street position in Q1 2026.
- Celldex Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #4431 holding.
- Jane Street first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 32 quarters since.
- Jane Street's Celldex Therapeutics position peaked at $7.42M in Q1 2024.
- 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.